AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36882134 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2211
Study 36882134 — intervention group
Group type: COMPARATOR
Intervention: Alert vs Usual Care
Number of subjects: 2211
Study 36882134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert vs Message
Number of subjects: 2211
Study 36882134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert
Number of subjects: 2211
Study 34303417 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational sessions and use of a dialogue tool
Number of subjects: 1470
Study 34303417 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 1470
Study 32605784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail/Plate
Number of subjects: 10
Study 32605784 — intervention group
Group type: COMPARATOR
Intervention: Dual-Plate
Number of subjects: 10
Study 35148434 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveHip+ rehabilitation (N=52)
Number of subjects: 104
Study 35148434 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=52)
Number of subjects: 104
Study 35234890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message condition
Number of subjects: 738
Study 35234890 — intervention group
Group type: COMPARATOR
Intervention: Control message condition
Number of subjects: 738
Study 34386281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Innovative Balance System (DIBA)
Number of subjects: 36
Study 34386281 — intervention group
Group type: COMPARATOR
Intervention: Control group (balance training using a balance board, a wobble board, the BOSU, or a soft cushion block)
Number of subjects: 36
Study 32265432 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video about anesthesia
Number of subjects: 121
Study 32265432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 121
Study 35615893 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month telerehabilitation
Number of subjects: 61
Study 35615893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 33562129 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention on hearing health (3 months duration)
Number of subjects: 830
Study 33562129 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 830
Study 32212518 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1.00 to 1.25 mg/kg)
Number of subjects: 336
Study 32212518 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 336
Study 32212518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 34021599 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST, min/day)
Number of subjects: 80
Study 34021599 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 80
Study 32268583 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual nutrient intakes and food sources assessment
Number of subjects: 1264
Study 32268583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity questionnaire and physical activity assessment
Number of subjects: 1264
Study 32268583 — intervention group
Group type: EXPERIMENTAL
Intervention: Top food sources of energy
Number of subjects: 1264
Study 35011579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib or Pazopanib (anti-angiogenic drugs)
Number of subjects: 86
Study 35839108 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine combined with Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 80
Study 35839108 — intervention group
Group type: COMPARATOR
Intervention: Goal-Directed Fluid Therapy (GDFT) alone
Number of subjects: 80
Study 33545615 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk scores (WGRSs) for PLT
Number of subjects: 17037
Study 33545615 — intervention group
Group type: COMPARATOR
Intervention: Chemerin level WGRSs
Number of subjects: 17037
Study 33230026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5-3 mg/d
Number of subjects: 0
Study 33230026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32885482 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures retained by 1 implant (Group I)
Number of subjects: 37
Study 32885482 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdentures retained by 2 implants (Group II)
Number of subjects: 37
Study 32885482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed hybrid prosthesis on 4 implants (Group III)
Number of subjects: 37
Study 34127158 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema therapy (ST)
Number of subjects: 103
Study 33571369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced RUTF
Number of subjects: 516
Study 33571369 — intervention group
Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 516
Study 32069294 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS over the parietal cortex
Number of subjects: 0
Study 32069294 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS over the prefrontal cortex
Number of subjects: 0
Study 32069294 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study 35437251 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS)
Number of subjects: 6
Study 35437251 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Trauma Care (PTC)
Number of subjects: 6
Study 35437251 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 6
Study 32729416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-immune gene pair signature (5-IRGPs)
Number of subjects: 542
Study 32729416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-IRGPs
Number of subjects: 542
Study 32066490 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention
Number of subjects: 1696
Study 32066490 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 1696
Study 35324465 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily with bevacizumab 10 mg/kg i.v. every 2 weeks
Number of subjects: 150
Study 35324465 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 10 mg daily
Number of subjects: 150
Study 33377368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based oral nutritional supplement (ONS)
Number of subjects: 38
Study 33377368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similarly flavored oral fluid)
Number of subjects: 38
Study 35943744 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led behavioral intervention from a certified peer recovery specialist (n=323)
Number of subjects: 648
Study 35943744 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention delivered by a hospital-employed licensed clinical social worker (n=325)
Number of subjects: 648
Study 34956561 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib capsules combined with PD-1 inhibitor (camrelizumab)
Number of subjects: 88
Study 34956561 — intervention group
Group type: COMPARATOR
Intervention: Single treatment group (STG) with anlotinib only
Number of subjects: 88
Study 32597302 — intervention group
Group type: EXPERIMENTAL
Intervention: PGx-guided treatment
Number of subjects: 100
Study 32597302 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 100
Study 35701155 — intervention group
Group type: EXPERIMENTAL
Intervention: T2T tapering strategy (N=81)
Number of subjects: 122
Study 35701155 — intervention group
Group type: COMPARATOR
Intervention: T2T no-tapering strategy (N=41)
Number of subjects: 122
Study 32577299 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function training (3 times a week for 30 min for 12 weeks)
Number of subjects: 30
Study 32577299 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 30
Study 32577299 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function training
Number of subjects: 30
Study 36073613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic therapy guided by viscoelastic hemostatic assays (VHA)
Number of subjects: 187
Study 36073613 — intervention group
Group type: COMPARATOR
Intervention: Hemostatic therapy guided by conventional coagulation tests (CCT)
Number of subjects: 187
Study 34520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy followed by 12 courses of adjuvant mFOLFOX6 chemotherapy
Number of subjects: 300
Study 34520230 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy alone
Number of subjects: 300
Study 35990136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling based on positive psychology
Number of subjects: 210
Study 35990136 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention measures (Control)
Number of subjects: 210
Study 33159530 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBAs)
Number of subjects: 0
Study 33159530 — intervention group
Group type: EXPERIMENTAL
Intervention: NMBAs
Number of subjects: 0
Study 33159530 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial neuromuscular blockade
Number of subjects: 0
Study 35173415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.294% (EC90)
Number of subjects: 58
Study 35173415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine concentration adjusted based on previous patient's response
Number of subjects: 58
Study 32222079 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 337
Study 32222079 — intervention group
Group type: COMPARATOR
Intervention: Institutional rearing
Number of subjects: 337
Study 35253331 — intervention group
Group type: EXPERIMENTAL
Intervention: DIY RT‐CGM with parental remote monitoring
Number of subjects: 55
Study 35253331 — intervention group
Group type: COMPARATOR
Intervention: isCGM plus usual diabetes care
Number of subjects: 55
Study 32768967 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 25 mg administered at noon and 30 min before bedtime for three months
Number of subjects: 26
Study 32768967 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at noon and 30 min before bedtime for three months
Number of subjects: 26
Study 32768967 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MEL)
Number of subjects: 26
Study 32768967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32768967 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (MEL) and Placebo
Number of subjects: 26
Study 35641569 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital support system with daily weight measurements
Number of subjects: 107
Study 35641569 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107
Study 34397733 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil massage (10 mL/kg/day of MCT oil divided into three applications)
Number of subjects: 48
Study 34397733 — intervention group
Group type: COMPARATOR
Intervention: Massage alone
Number of subjects: 48
Study 34397733 — intervention group
Group type: COMPARATOR
Intervention: No massage
Number of subjects: 48
Study 32993528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral block (PVB) with 20 mL 0.25% bupivacaine as a single administration.
Number of subjects: 44
Study 32993528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 44
Study 36127337 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oxytocin (24 international units)
Number of subjects: 38
Study 36127337 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose oxytocin (4 weeks of once-daily nasal spray)
Number of subjects: 38
Study 36127337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32715972 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tourniquet procedure
Number of subjects: 78
Study 32715972 — intervention group
Group type: COMPARATOR
Intervention: Control group (tourniquet procedure)
Number of subjects: 78
Study 35218301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 2000 IU/day (group A)
Number of subjects: 24
Study 35218301 — intervention group
Group type: COMPARATOR
Intervention: Acitretin 0.5 mg/kg/day (group B)
Number of subjects: 24
Study 35218301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 24
Study 32833858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 32833858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 302
Study 32833858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 302
Study 33955547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet (VD) for 3 months
Number of subjects: 107
Study 33955547 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (MD) for 3 months
Number of subjects: 107
Study 32590942 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg rifabutin every other day (E.O.D) with lopinavir/ritonavir
Number of subjects: 16
Study 32590942 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg rifabutin every other day (E.O.D) with lopinavir/ritonavir
Number of subjects: 16
Study 33731069 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment of 13+ years
Number of subjects: 8698
Study 33731069 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment of 10-12 years
Number of subjects: 8698
Study 33731069 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper family average income (FAI) tertile
Number of subjects: 8698
Study 33731069 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle family average income (FAI) tertile
Number of subjects: 8698
Study 33731069 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation as white collar
Number of subjects: 8698
Study 33681731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg BID x1day, followed by 200 mg BID x9days
Number of subjects: 231
Study 33681731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine with Azithromycin (HCQ/AZ) 500 mg, then 250 mg daily x4days
Number of subjects: 231
Study 33681731 — intervention group
Group type: COMPARATOR
Intervention: Control (ascorbic acid (HCQ) and folic acid (AZ))
Number of subjects: 231
Study 35219715 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented double WACA lesion set
Number of subjects: 0
Study 35219715 — intervention group
Group type: COMPARATOR
Intervention: Single WACA lesion set (Control)
Number of subjects: 0
Study 34080094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy
Number of subjects: 55
Study 34080094 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 55
Study 32022664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 100
Study 32022664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 100
Study 32022664 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (ZOL)
Number of subjects: 100
Study 32022664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 100
Study 35722886 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 2 g/day
Number of subjects: 40
Study 35722886 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 40
Study 34225782 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinely recorded data
Number of subjects: 98
Study 34225782 — intervention group
Group type: COMPARATOR
Intervention: Data collected using case report forms
Number of subjects: 98
Study 32573156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicro needle‐knife and cervical spine fine adjusting
Number of subjects: 86
Study 32573156 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture and manipulation
Number of subjects: 86
Study 35105389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 soya:dairy blend
Number of subjects: 16
Study 35105389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:2 soya:dairy blend
Number of subjects: 16
Study 35105389 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 16
Study 33263718 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1231
Study 33263718 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 1231
Study 34498507 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab monotherapy
Number of subjects: 33
Study 34454582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial manipulation (FM) and sequential yoga poses (SYP)
Number of subjects: 160
Study 34454582 — intervention group
Group type: COMPARATOR
Intervention: Cervical mobilization/ thoracic manipulation and therapeutic exercises (usual care)
Number of subjects: 160
Study 34678847 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 44
Study 34678847 — intervention group
Group type: COMPARATOR
Intervention: QuizTime
Number of subjects: 44
Study 34678847 — intervention group
Group type: COMPARATOR
Intervention: Experiential
Number of subjects: 44
Study 34056848 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior iliac crest bone grafts
Number of subjects: 20
Study 34056848 — intervention group
Group type: COMPARATOR
Intervention: Calvarial bone grafts
Number of subjects: 20
Study 36091679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 304
Study 36091679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 33307947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 40
Study 33307947 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active control)
Number of subjects: 40
Study 35263150 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT])
Number of subjects: 599
Study 35263150 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [CRT])
Number of subjects: 599
Study 35263150 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term radiotherapy (TNT)
Number of subjects: 599
Study 35263150 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 599
Study 34524004 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with Paclitaxel and Cisplatin (Apa+TP)
Number of subjects: 126
Study 34524004 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and Cisplatin (TP)
Number of subjects: 126
Study 32467402 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP with HME filter
Number of subjects: 10
Study 32467402 — intervention group
Group type: COMPARATOR
Intervention: Helmet CPAP without HME filter
Number of subjects: 10
Study 34102092 — intervention group
Group type: EXPERIMENTAL
Intervention: Television on National Geographic channel (NG)
Number of subjects: 10
Study 34102092 — intervention group
Group type: EXPERIMENTAL
Intervention: Television with MemoRide software (MR)
Number of subjects: 10
Study 34102092 — intervention group
Group type: COMPARATOR
Intervention: Television off (TV off)
Number of subjects: 10
Study 34102092 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 10
Study 33108617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 32970784 — intervention group
Group type: EXPERIMENTAL
Intervention: Group social support intervention via virtual reality, 14 sessions over 6 months, led by community coordinators and volunteers.
Number of subjects: 34
Study 32970784 — intervention group
Group type: COMPARATOR
Intervention: Delayed condition (waitlist control group).
Number of subjects: 34
Study 35303968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainstream capnography using an inner cup via face mask (novel method)
Number of subjects: 60
Study 35303968 — intervention group
Group type: COMPARATOR
Intervention: Sidestream capnography (previous method)
Number of subjects: 60
Study 32693320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation treatment
Number of subjects: 26
Study 32693320 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 10)
Number of subjects: 26
Study 34259635 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-initiated treatment
Number of subjects: 191
Study 34259635 — intervention group
Group type: COMPARATOR
Intervention: Self-paced treatment
Number of subjects: 191
Study 35561092 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time remote access to child's glucose and insulin data by healthcare professionals
Number of subjects: 30
Study 35561092 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote consultations during the COVID-19 pandemic
Number of subjects: 30
Study 35561092 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time data sharing in routine clinical care
Number of subjects: 30
Study 35561092 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations for closed-loop system users in routine clinical care
Number of subjects: 30
Study 32725199 — intervention group
Group type: COMPARATOR
Intervention: 12-week regimen
Number of subjects: 658
Study 32725199 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week regimen
Number of subjects: 658
Study 34263385 — intervention group
Group type: EXPERIMENTAL
Intervention: BAK-preserved latanoprost
Number of subjects: 44
Study 34263385 — intervention group
Group type: COMPARATOR
Intervention: polyquad-preserved travoprost
Number of subjects: 44
Study 33559635 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI instrumentation
Number of subjects: 0
Study 33559635 — intervention group
Group type: COMPARATOR
Intervention: STD instrumentation
Number of subjects: 0
Study 34716558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 6376
Study 34716558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 6376
Study 34716558 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for survival outcomes
Number of subjects: 6376